# Project 3 - Long Intergenic Non-Coding RNAs in the Malignant Progression of Barrett's Esophagus

> **NIH NIH U54** · CASE WESTERN RESERVE UNIVERSITY · 2021 · $289,800

## Abstract

Project Summary/Abstract 
The incidence of esophageal adenocarcinoma (EAC) has increased at an alarming rate (>500%) in the last few 
decades, far exceeding any other cancer type, in the United States. The prognosis for EAC patients remains 
poor with very limited treatment options. Although Barrett’s esophagus (BE), a columnar metaplasia of the distal- 
esophagus epithelium, is the only known precursor of EAC, the vast majority of BE patients however do not 
develop dysplasia or cancer; consequently the factors driving progression from BE to EAC remain elusive. Our 
long-term objective is to elucidate the mechanisms underlying EAC progression, such that reliable biomarkers 
and targeted therapies can be developed for effective management of this deadly disease. Recently, using 
innovative RNA sequencing in BE-associated lesions, we identified two large intergenic non-coding RNAs 
(lincRNAs) showing marked and selective inductions in ~50% of EAC lesions. Both lincRNAs exhibited nuclear 
localization, and preliminary functional assessments strongly suggested these lincRNAs to play pro-tumorigenic 
roles during EAC progression. Our study thus provides the first global analysis of lincRNAs in this disease, 
identifying two novel lincRNAs with potential oncogenic roles in esophageal carcinogenesis. Accordingly, the 
specific goals of the current proposal are: (AIM 1) To elucidate the function of candidate EAC-associated 
lincRNAs. We will generate CRISPR/Cas9-based inducible lincRNA-knockout EAC cell line models to 
comprehensively characterize the phenotypic effects of candidate lincRNAs using both in vitro, and in vivo 
xenograft experimental systems; (AIM 2) To dissect the molecular regulatory networks upstream and 
downstream of EAC-associated lincRNAs. We will evaluate for potential genomic/epigenomic mechanisms 
driving lincRNA expression in EACs; using the EAC cell line models, we will perform global gene expression 
microarray profiling to delineate the genes/pathways modulated by the lincRNAs; and we will use ChIRP-seq/- 
MS approaches to map the genomic occupancy and to identify potential gene targets and protein partners of 
candidate lincRNAs, thus establishing a regulatory-roadmap of candidate lincRNAs; (AIM 3) To determine the 
timing and stage-associated deregulations in candidate lincRNAs during EAC progression. Our preliminary 
findings showed both lincRNAs being induced in high-grade dysplasia (HGD), a histopathologic surrogate for 
EAC risk. Accordingly, we will validate and ascertain the frequency of lincRNA deregulations in these overtly 
pre-malignant phases of disease progression. Additionally, we will test: whether non-dysplastic BE lesions, 
within close proximity to EAC, show induction of these candidate lincRNAs; and whether candidate lincRNAs 
show induction early-on in non-dysplastic BE/low-grade dysplasia (LGD) mucosa, derived from high-risk patients 
who developed cancer during follow-up. Success in these studies will u...

## Key facts

- **NIH application ID:** 10153704
- **Project number:** 5U54CA163060-10
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** Kishore Guda
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $289,800
- **Award type:** 5
- **Project period:** 2011-09-26 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10153704

## Citation

> US National Institutes of Health, RePORTER application 10153704, Project 3 - Long Intergenic Non-Coding RNAs in the Malignant Progression of Barrett's Esophagus (5U54CA163060-10). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10153704. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
